Ellagic acid and montelukast mitigate arsenic trioxide–induced hepatotoxicity via modulation of oxidative stress, inflammatory pathways, and mitochondrial apoptosis
Naunyn-Schmiedeberg's Archives of Pharmacology · 2026
DOI: 10.1007/s00210-026-05536-x ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2026. Verfasst von Maryam Gharibi und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Student Research Committee, Dezful University of Medical Sciences, Dezful, Iran. Hauptthemen laut MEDLINE: Quinolines, Chemical and Drug Induced Liver Injury, Ellagic Acid, Acetates. Die Arbeit nennt 76 Literaturangaben.
Abstract (Originalsprache)
Arsenic trioxide (As_2O_3) is an effective therapeutic agent for acute promyelocytic leukemia. However, its clinical application is limited by hepatotoxicity, mainly linked to oxidative stress, inflammatory activation, and mitochondrial dysfunction. This study investigated whether ellagic acid (EA) and montelukast (MK), alone or together, protect against As_2O_3-induced liver injury in mice. Male NMRI mice were treated with As_2O_3 in the presence or absence of EA and MK for 10 days. After treatment, we performed biochemical, molecular, mitochondrial, and histopathological evaluations. As_2O_3 exposure led to pronounced hepatic injury, which was evident from elevated liver enzyme levels, increased lipid peroxidation, raised pro-inflammatory cytokines, reduced mitochondrial membrane potential, and increased apoptosis indices. Administration of EA or MK alone partly reduced several of these parameters. In contrast, concurrent use of EA and MK produced more marked improvements, including normalization of liver enzymes, enhanced antioxidant enzyme activity, lower pro-inflammatory and apoptotic markers, and preserved mitochondrial function. These protective effects were supported by consistently improved liver histopathology. In conclusion, combined EA and MK administration reduces As_2O_3-induced hepatotoxicity. This protection occurs by modulating oxidative stress, inflammation, and mitochondrial-dependent apoptosis. These findings indicate that targeting several processes could help reduce liver side effects from arsenic-based chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Student Research Committee, Dezful University of Medical Sciences, Dezful, Iran.
- Department of Physiology, School of Medicine, Dezful University of Medical Sciences, Dezful, Iran.
- Department of Histology, School of Medicine, Dezful University of Medical Sciences, Dezful, Iran.
- Department of Pharmacology, School of Medicine, Dezful University of Medical Sciences, Dezful, Iran.
- Department of Pharmacology, School of Medicine, Dezful University of Medical Sciences, Dezful, Iran. soheila.alb@gmail.com.
Zitieren
APA
Gharibi, M., Oroojan, A. A., Behmanesh, M. A., Amirgholami, N., Etedali, H., & Alboghobeish, S. (2026). Ellagic acid and montelukast mitigate arsenic trioxide–induced hepatotoxicity via modulation of oxidative stress, inflammatory pathways, and mitochondrial apoptosis. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-026-05536-x
Vancouver
Gharibi M, Oroojan AA, Behmanesh MA, Amirgholami N, Etedali H, Alboghobeish S. Ellagic acid and montelukast mitigate arsenic trioxide–induced hepatotoxicity via modulation of oxidative stress, inflammatory pathways, and mitochondrial apoptosis. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-026-05536-x
BibTeX
@article{Gharibi2026,
author = {Gharibi, Maryam and Oroojan, Ali Akbar and Behmanesh, Mohammad Amin and Amirgholami, Neda and Etedali, Hooman and Alboghobeish, Soheila},
title = {Ellagic acid and montelukast mitigate arsenic trioxide–induced hepatotoxicity via modulation of oxidative stress, inflammatory pathways, and mitochondrial apoptosis},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2026},
doi = {10.1007/s00210-026-05536-x}
}
EUVIMED